ESC 365 - Controversies in ablation therapy: asymptomatic atrial fibrillation and atrial fibrillation in heart failure

EHRA Premium Access

Controversies in ablation therapy: asymptomatic atrial fibrillation and atrial fibrillation in heart failure

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Atrial fibrillation (AF)

Session type: Debate Session

Date: 19 June 2017

Time: 11:00 - 12:30

Session

8 presentations in this session

Patients with paroxysmal atrial fibrillation should undergo ablation, even if asymptomatic, to prevent stroke and life-long anticoagulation - PRO.

Speaker: Doctor D. Packer (Rochester, US)

Patients with paroxysmal atrial fibrillation should undergo ablation, even if asymptomatic, to prevent stroke and life-long anticoagulation - CONTRA.

Speaker: Professor F. Braunschweig (Stockholm, SE)

Rebuttal - PRO.

Rebuttal - CONTRA.

Ablation of atrial fibrillation should be used frequently in heart failure - PRO.

Speaker: Professor L. Di Biase (The Bronx, US)

Atrial fibrillation ablation is rarely needed in heart failure - CONTRA.

Speaker: Professor F. Ruschitzka (Zurich, CH)

Rebuttal - PRO.

Rebuttal - CONTRA.

4 speakers from this session

Doctor Douglas L Packer

Mayo Clinic Hospital - St. Mary's Campus, Rochester (United States of America)

12 presentations

0 follower

Professor Frieder Braunschweig

Karolinska University Hospital, Stockholm (Sweden)

14 presentations

0 follower

Professor Luigi Di Biase

Albert Einstein College of Medicine at Montefiore Hospital, The Bronx (United States of America)

20 presentations

0 follower

Professor Frank Ruschitzka

University Heart Center, Zurich (Switzerland)

81 presentations

2 followers

This platform is supported by